At the time of writing, Boston Scientific Corp. [BSX] stock is trading at $87.45, down -0.64%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BSX shares have gain 0.52% over the last week, with a monthly amount glided 4.72%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Boston Scientific Corp. [NYSE: BSX] stock has seen the most recent analyst activity on October 18, 2024, when Needham downgraded its rating to a Hold. Previously, Goldman started tracking the stock with Buy rating on May 30, 2024, and set its price target to $90. On February 01, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $80 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $59 on July 19, 2023. CL King initiated its recommendation with a Buy and recommended $64 as its price target on June 30, 2023. In a note dated March 29, 2023, UBS initiated an Buy rating and provided a target price of $57 on this stock.
For the past year, the stock price of Boston Scientific Corp. fluctuated between $49.15 and $88.79. Currently, Wall Street analysts expect the stock to reach $73.74 within the next 12 months. Boston Scientific Corp. [NYSE: BSX] shares were valued at $87.45 at the most recent close of the market. An investor can expect a potential drop of -15.68% based on the average BSX price forecast.
Analyzing the BSX fundamentals
According to Boston Scientific Corp. [NYSE:BSX], the company’s sales were 15.23B for trailing twelve months, which represents an 14.48% jump. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 84.62 points at the first support level, and at 81.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 88.93, and for the 2nd resistance point, it is at 90.41.
Ratios To Look Out For
It is important to note that Boston Scientific Corp. [NYSE:BSX] has a current ratio of 1.61. Further, the Quick Ratio stands at 1.14, while the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 8.46, the price to book ratio is 6.31 and price to earnings (TTM) ratio is 70.75.
Transactions by insiders
Recent insider trading involved Mahoney Michael F, Chairman, President & CEO, that happened on Oct 07 ’24 when 0.16 million shares were sold. EVP & Group Pres, Cardiology, Fitzgerald Joseph Michael completed a deal on Oct 07 ’24 to sell 0.13 million shares. Meanwhile, Officer JOSEPH M FITZGERALD bought 0.13 million shares on Oct 07 ’24.
